The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 3, 2003, Pages 821-827

  Terry Jr , Alvin V ^a,b   Buccafusco, J J ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ATROPINE; CHOLINE; CHOLINE ACETYLTRANSFERASE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GLYCOPYRRONIUM BROMIDE; MECAMYLAMINE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROTROPHIN; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; PIRENZEPINE; RIVASTIGMINE; SCOPOLAMINE; TACRINE;

ACETYLCHOLINE RELEASE; ADULT; AGED; AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; COGNITIVE DEFECT; DEMENTIA; ENZYME ACTIVITY; HUMAN; NERVE FIBER TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SENILE PLAQUE;

ACETYLCHOLINE; AGING; ALZHEIMER DISEASE; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; HUMANS;

EID: 0042433479     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.041616     Document Type: Review

References (65)

1. Allen DD, Galdzicki Z, Brining SK, Fukuyama R, Rapoport SI, and Smith QR (1997) β-Amyloid induced increase in choline flux across PC12 cell membranes. Neurosci Lett 234:71-73.
2. Apelt J, Kumar A, and Schliebs R (2002) Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human beta-amyloid precursor protein. Brain Res 953:17-30.
3. Auld DS, Kornecook TJ, Bastianetto S, and Quirion R (2002) Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition and treatment strategies. Prog Neurobiol 68:209-245.
4. Bartus RT (2000) On neurodegenerative diseases, models and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163:495-529.
5. Buccafusco JJ and Terry AV Jr (2000) Multiple CNS targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther 295:438-446.
6. Burk JA, Herzog CD, Porter MC, and Sarter M (2002) Interactions between aging and cortical cholinergic deafferentation on attention. Neurobiol Aging 23:467-477.
7. Cummings JL (2003) Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 11:131-145.
8. Dai J, Buijs RM, Kamphorst W, and Swaab DF (2002) Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes. Brain Res 948:138-144.
9. 2+ dependent mechanism. Neuropharmacology 39:2799-2807.
10. Damasio AR, Graff-Radford NR, Eslinger PJ, Damasio H, and Kassell N (1985) Amnesia following basal forebrain lesions. Arch Neurol 42:263-271.
11. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, and Haroutunian V (1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. J Am Med Assoc 281:1401-1406.
12. Decker MW and McGaugh JL (1991) The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7:151-168.
13. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ (2002) Up-regulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51:145-155.
14. Deutsch JA (1971) The cholinergic synapse and the site of memory. Science (Wash DC) 174:788-794.
15. Elrod K and Buccafusco JJ (1991) Correlation of the amnestic effects of nicotinic antagonists with inhibition of regional brain acetylcholine synthesis in rats. J Pharmacol Exp Ther 258:403-409.
16. Eustace A, Coen R, Walsh C, Cunningham CJ, Walsh JB, Coakley D, and Lawlor BA (2002) A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer's disease. Int J Geriatr Psychiatry 17:968-973.
17. Fisher A, Brandeis R, Bar-Ner RHN, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, and Pittel Z (2002) AF150s and AF267B. M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci 19:145-153.
18. Flicker C, Ferris SH, and Serby M (1992) Hypersensitivity to scopolamine in the elderly. Psychopharmacology (Berl) 107:437-441.
19. Furey ML, Pietrini P, and Haxby JV (2000) Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science (Wash DC) 290:2315-2319.
20. Genis I, Fisher A, and Michaelson DM (1999) Site specific dephosphorylation of tau in apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment. J Neurochem 12:206-213.
21. Gibson GE and Peterson C (1981) Aging decreases oxidative metabolism and the release and synthesis of acetylcholine. J Neurochem 37:978-984.
22. Gibson GE, Peterson C, and Sansone J (1981) Neurotransmitter and carbohydrate metabolism during aging and mild hypoxia. Neurobiol Aging 2:165-172.
23. Gilad GM, Rabey JM, Tizabi Y, and Gilad VH (1987) Age-dependent loss and compensatory changes of septohippocampal cholinergic neurons in two rat strains differing in longevity and response to stress. Brain Res 436:311-322.
24. Gilmor ML, Erickson JD, Varoqui H, Hersh LB, Bennett DA, Cochran EJ, Mufson EJ, and Levey AI (1999) Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. Comp Neurol 411:693-704.
25. Grantham C and Geerts H (2002) The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease. J Neurol Sci 203-204:131-136.
26. 1 muscarinic receptor to β-amyloid precursor protein secretion. J Neurochem 71:2094-2103.
27. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K and Morgan D (1999) Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Gen 29:177-185.
28. Hunter AJ and Roberts FF (1988) The effect of pirenzepine on spatial learning in the Morris Water Maze. Pharmacol Biochem Behav 30:519-523.
29. Jhamandas JH, Cho C, Jassar B, Harris K, MacTavish D, and Easaw J (2001) Cellular mechanisms for amyloidβ-protein activation of rat cholinergic basal fore-brain neurons. J Neurophysiol 86:1312-1320.
30. Jonnala RR, Terry AV Jr, and Buccafusco JJ (2002) Nicotine increases the expression of high affinity nerve growth factor receptors both in vitro and in vivo. Life Sci 70:1543-1554.
31. Kar S, Issa AM, Seto D, Auld DS, Collier B, and Quirion R (1998) Amyloidβ-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J Neurochem 70:2179-2187.
32. Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, and Akaike A (1997) Nicotine receptor stimulation protects neurons against β-amyloid toxicity. Ann Neurol 42:159-163.
33. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, and Ashe KH (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22:6331-6335.
34. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA, and Kilbourn MR (1999) In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 52:691-699.
35. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, and Koeppe RA (1996) In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease and Parkinson's disease. Ann Neurol 40:399-410.
36. Levin ED (1992) Nicotinic systems and cognitive function. Psychopharmacol 108:417-431.
37. Liu Q-S, Kawai H, and Berg DW (2001) β-Amyloid peptide blocks the response of β7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 98:4734-4739.
38. Meyer EM, Crews FT, Otero DH, and Larsen K (1986) Aging decreases the sensitivity of rat cortical synaptosomes to calcium ionophore-induced acetylcholine release. J Neurochem 47:1244-1246.
39. Minger SL, Esiri MM, McDonald B, Keene J, Carter J, Hope T, and Francis PT (2000) Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 55:1460-1467.
40. Moore H, Stuckman W, Sarter M, and Bruno JP (1996) Potassium, but not atropine-stimulated cortical acetylcholine efflux is reduced in aged rats. Neurobiol Aging 17:565-571.
41. Morris JC (2002) Challenging assumptions about Alzheimer's disease: mild cognitive impairment and the cholinergic hypothesis. Ann Neurol 51:143-144.
42. Mufson EJ, Kroin JS, Sendera TJ, and Sobreviela T (1999) Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 57:451-84.
43. Muller DM, Mendla K, Farber SA, and Nitsch RM (1997) Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci 60:985-991.
44. Newhouse PA, Potter A, Corwin J, and Lenox R (1994) Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacol 10:93-107.
45. 3H-acetylcholine efflux from Alzheimer brain slices to normal level. J Neural Transm 67:275-285.
46. Nordberg A (2001) Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psychiatry 49:200-210.
47. Owman C, Fuxe K, Jason AM, and Kahrstrom J (1989) Studies of protective actions of nicotine on neuronal and vascular functions in rats: comparison between sympathetic noradrenergic and mesostriatal dopaminergic fiber system and the effect of a dopamine agonist. Prog Brain Res 79:267-276.
48. Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, Nasland J, Davis K, et al. (2000) Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 393:215-222.
49. Perry E, Walker M, Grace J, and Perry R (1999) Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 22:273-280.
50. Picciotto MR and Zoli M (2002) Nicotinic receptors in aging and dementia. J Neurobiol 53:641-655.
51. Ray PG, Meador KJ, Loring DW, Zamrini EW, Yang X-H, and Buccafusco JJ (1992) Central anticholinergic hypersensitivity in aging. J Geriat Psych Neurol 5:72-77.
52. Ruske AC and White KG (1999) Facilitation of memory performance by a novel muscarinic agonist in young and old rats. Pharmacol Biochem Behav 63:663-667.
53. 1-muscarinic acetylcholine receptor regulates TAU phosphorylation in transfected PC12 cells. J Neurochem 66:877-880.
54. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science (Wash DC) 298:789-791.
55. Slotkin TA, Seidler FJ, Crain BJ, Bell JM, Bissette G, and Nemeroff CB (1990) Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy. Proc Natl Acad Sci USA 87:2452-2455.
56. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA 3rd, and Murphy DL (1987) Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry 44:418-426.
57. Terry AV, Buccafusco JJ, and Jackson WJ (1993a). Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance in monkeys. Pharmacol Biochem Behav 45:925 929.
58. Terry AV, Jackson WJ, and Buccafusco JJ (1993b) Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by young and aged monkeys. Cerebral Cortex 3:304-312.
59. Terry AV, Risbrough VB, Buccafusco JJ, and Menzaghi F (2002) Effects of (±)-4-{(2-(1-methyl-2-pyrrolidinyl)ethyl]thio}phenol Hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. J Pharmacol Exp Ther 301:284-292.
60. Vitiello B, Martin A, Hill J, Mack C, Molchan S, Martinez R, Murphy DL, and Sunderland T (1997) Cognitive and behavioral effects of cholinergic, dopaminergic and serotonergic blockade in humans. Neuropsychopharmacol 16:15-24.
61. Wang HY, Lee DH, Davis CB, and Shank RP (2000) Amyloid peptide Aβ (1-42) binds selectively and with picomolar affinity to α7 nicotinic acetylcholine receptors. J Neurochem 75:155-1161.
62. Woodruff-Pak DS, Lander C, and Geerts H (2002) Nicotinic cholinergic modulation: galantamine as a prototype. Cent Nerv Syst Drugs Rev 8:405-426.
63. Wu CF, Bertorelli R, Sacconi M, Pepeu G, and Consolo S (1988) Decrease of brain acetylcholine release in aging freely-moving rats detected by microdialysis. Neurobiol Aging 9:357-361.
64. Zemishlany Z and Thorne AE (1991) Anticholinergic challenge and cognitive functions: a comparison between young and elderly normal subjects. Isr J Psychiatry Relat Sci 28:32-41.
65. 11C]NMPB and PET. Synapse 39:275-287.